Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPV4 | Q9HBA0 | 1/20 | 0.40 |
| ▸ | RXRA | P19793 | 1/20 | 0.32 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.32 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.32 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.31 |
| ▸ | CRHBP | P24387 | 1/20 | 0.30 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.30 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29772311 | 1.00 | TRPV4 (0.40) | TRPV4RXRAGRIN1GRIN2BROCK1 | |
| SCHEMBL23169319 | 0.77 | MCHR1 (0.36) | CRHBPCRHR2 | |
| SCHEMBL29772312 | 0.77 | MCHR1 (0.36) | CRHBPCRHR2 | |
| SCHEMBL3380041 | 0.71 | PDE4A (0.38) | PDE4D | |
| SCHEMBL30670499 | 0.70 | LMNA (0.38) | — | |
| SCHEMBL24716239 | 0.70 | LMNA (0.38) | — | |
| SCHEMBL9194413 | 0.69 | RXRA (0.45) | TRPV4RXRAGRIN1GRIN2BROCK1 | |
| SCHEMBL28359202 | 0.68 | CRHBP (0.37) | TRPV4ROCK1CRHBPCRHR2 | |
| SCHEMBL19844889 | 0.68 | MBOAT4 (0.38) | TRPV4CRHBPCRHR2 | |
| SCHEMBL16463280 | 0.67 | NOS3 (0.41) | ROCK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260076968-A1 | AZA-QUINOLINE COMPOUNDS AND USES THEREOF | NOVARTIS AG (CH) | 2026-03-19 | — | — | US | disclosed |
| EP-4034535-B1 | AZA-QUINOLINE COMPOUNDS AND USES THEREOF | NOVARTIS AG (CH) | 2026-03-04 | — | — | EP | disclosed |
| US-12544374-B2 | AZA-quinoline compounds and uses thereof | NOVARTIS AG (CH) | 2026-02-10 | — | — | US | disclosed |
| US-20220280509-A1 | AZA-QUINOLINE COMPOUNDS AND USES THEREOF | NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH, INC. | 2022-09-08 | — | — | US | disclosed |
| US-20220280509-A1 | AZA-QUINOLINE COMPOUNDS AND USES THEREOF | NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH, INC. | 2022-09-08 | — | — | US | disclosed |
| CN-114746414-A | Aza-quinoline compounds and uses thereof | 诺华公司 | 2022-07-12 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260076968-A1 | AZA-QUINOLINE COMPOUNDS AND USES THEREOF | EZH2, SUZ12, NR3C1 | TRPV4 4744/4885RXRA 209/4885GRIN1 240/4885 |
| US-12544374-B2 | AZA-quinoline compounds and uses thereof | EZH2, NR3C1, SUZ12 | TRPV4 4807/4885RXRA 274/4885GRIN1 142/4885 |
| US-20220280509-A1 | AZA-QUINOLINE COMPOUNDS AND USES THEREOF | EZH2, BMI1, EED | TRPV4 4829/4885RXRA 476/4885GRIN1 438/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.